UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

Mark one
|X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30,1999

or

|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to _____________

Commission File Number 1-9974

ENZO BIOCHEM, INC.

(Exact name of registrant as specified in its charter)

NEW YORK	13-2866202
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
60 EXECUTIVE BLVD., FARMINGDALE, NEW YORK	11735
(Address of principal executive office)	(Zip Code)

(516-755-5500)

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

COMMON STOCK, $0.01 PAR VALUE	THE AMERICAN STOCK EXCHANGE
(Title of Class)	(Name of each Exchange on which Registered)

Securities registered pursuant to Section 12(g) of the Act:

NONE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant has required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes |X| No |_|

As of June 7, 1999 the Registrant had 24,925,000 shares of Common Stock outstanding.

ENZO BIOCHEM, INC.

FORM 10-Q

April 30, 1999

INDEX

ENZO BIOCHEM, INC.
PART 1 - FINANCIAL INFORMATION

Item 1. Financial Statements

CONSOLIDATED BALANCE SHEET

<TABLE>
<CAPTION>

<S>	April 30, 1999 (unaudited) <C>	July 31, 1998 <C>
	(in Thousands)	
ASSETS		
Current assets:		
Cash and cash equivalents	$41,863	$33,543
Accounts receivable, less allowance for doubtful accounts	14,477	14,195
Current portion of note receivable - litigation settlement	--	4,942
Inventories	1,393	1,393
Deferred taxes	471	471
Other	865	844
Total current assets	59,069	55,388
Property and equipment, at cost, less accumulated depreciation and amortization	2,619	2,570
Cost in excess of fair value of net tangible assets acquired, less accumulated amortization	8,656	8,934
Deferred patent costs, less accumulated Amortization	4,384	4,559
Deferred taxes	554	554
Other	119	148
	$75,401	$72,153

</TABLE>

ENZO BIOCHEM, INC.
LIABILITIES AND STOCKHOLDERS' EQUITY

<TABLE>
<CAPTION>

<S>	April 30, 1999 (unaudited) <C>	July 31, 1998 <C>
	(in Thousands)	
Current liabilities:		
Trade accounts payable	$ 1,016	$ 1,439
Income taxes payable	50	164
Other accrued expenses	725	803
Current portion of long-term debt	--	9
Total current liabilities	1,791	2,415
Other deferred liabilities	955	955
Stockholders' equity:		
Preferred Stock, $ .01 par value; authorized 25,000,000 shares; no shares issued or outstanding		
Common Stock, $ .01 par value; authorized 75,000,000 shares; shares issued and outstanding; 24,906,600 shares at April		

30,1999 and 24,905,300, shares at July 31,1998	249	249
Additional paid-in capital	92,270	92,103
Accumulated deficit	(19,864)	(23,569)
Total stockholders' equity	72,655	68,783
	$ 75,401	$ 72,153

</TABLE>

See accompanying notes

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited)

<TABLE>
<CAPTION>

	Nine Months Ended April 30, 1999	1998
	(In thousands, except per share data)	
<S>	<C>	<C>
Revenues:		
Research product revenues	$ 12,275	$ 9,457
Clinical laboratory services	21,443	20,880
Total operating revenues	33,718	30,337
Costs and expenses:		
Cost of research product revenues	6,039	5,442
Cost of clinical laboratory services	6,186	6,048
Research and development expense	3,380	2,931
Selling expense	2,039	2,039
Provision for uncollectable accounts Receivable	7,885	7,658
General and administrative expenses	5,806	5,537
Total costs and expenses	31,335	29,655
Income before interest income and provision for taxes on income	2,383	682
Interest income - net	1,475	1,403
Income before provision for taxes on income	3,858	2,085
Provision for taxes on income	(153)	(101)
Net income	$ 3,705	$ 1,984
Net income per common share:		
Basic	$ .15	$ .08
Diluted	$ .15	$ .08
Denominator for per share calculation:		
Basic	24,901	24,483
Diluted	25,520	25,550

</TABLE>

See accompanying notes

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited)

<TABLE>
<CAPTION>

	Three Months Ended April 30, 1999	1998
	(In thousands, except per share data)	

<S> <C> <C>

Revenues:		
Research product revenues	$ 4,928	$ 3,441
Clinical laboratory services	7,265	7,256
	--------	--------
Total operating revenues	12,193	10,697
Costs and expenses:		
Cost of research product revenues	2,315	2,082
Cost of clinical laboratory services	2,133	2,086
Research and development expense	1,083	809
Selling expense	640	685
Provision for uncollectable accounts Receivable	2,927	2,675
General and administrative expenses	1,834	1,912
	--------	--------
Total costs and expenses	10,932	10,249
	--------	--------
Income before interest income and provision for taxes on income	1,261	448
Interest income - net	458	508
	---	---
Income before provision for taxes on income	1,719	956
Provision for taxes on income	(37)	(53)
	--------	--------
Net income	$ 1,682	$ 903
	========	========
Net income per common share:		
Basic	$ .07	$ .04
	========	========
Diluted	$ .07	$ .04
	========	========
Denominator for per share calculation:		
Basic	24,907	24,463
	========	========
Diluted	25,530	25,530
	========	========

</TABLE>

See accompanying notes

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)

<TABLE>
<CAPTION>

	Nine Months Ended April 30, 1999	1998
	(In Thousands)	
<S>	<C>	<C>
Cash flows from operating activities:		
Net income	$ 3,705	$ 1,984
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization of property and equipment	645	638
Amortization of costs in excess of fair value of tangible assets acquired	278	278
Amortization of deferred patent costs	499	510
Issuance of warrants as compensation for services performed	50	--
Provision for uncollectable accounts receivable	7,785	7,658
Accretion of interest on note receivable	(58)	(215)
Other	--	119
Change in assets and liabilities:		
Note receivable - J & J settlement	5,000	5,000
Accounts receivable before provision for uncollectable amounts	(8,066)	(9,270)
Inventories	--	75
Other	(21)	780
Trade accounts payable and other accrued Expenses	(501)	(212)
Income taxes payable	(114)	--
Accrued legal fees	--	(45)

Total adjustments	5,497	5,316
Net cash provided by operating activities	$ 9,202	$ 7,300

</TABLE>

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)

<TABLE>
<CAPTION>

	Nine Months Ended April 30,	
	1999	1998
	(In Thousands)	
<S>	<C>	<C>
Cash flows from investing activities:		
Capital expenditures	(694)	(322)
Patent costs deferred	(325)	(334)
Security deposits	29	4
Net cash used in investing activities	(990)	(652)
Cash flows from financing activities:		
Payments of obligations under capital lease and long term debt	(9)	(37)
Proceeds from exercise of stock options	117	163
Net cash provided by financing activities	108	126
Net increase in cash and cash equivalents	8,320	6,774
Cash and cash equivalents at the beginning of the year	33,543	25,250
Cash and cash equivalents at the end of the period	$ 41,863	$ 32,024

</TABLE>

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
April 30, 1999
(Unaudited)

1. The consolidated balance sheet as of April 30, 1999, the consolidated statement of operations for three and nine months ended April 30,1999 ("1999 Period") and 1998 ("1998 Period") and the consolidated statement of cash flows for the nine months ended April 30, 1999 and 1998 have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at April 30, 1999 and for all periods presented have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company's 1998 Annual Report on Form 10-K. The results of operations for the nine months ended April 30, 1999 are not necessarily indicative of the results that may be expected for the full year.

In fiscal 1997, the Financial Accounting Standards Board issued SFAS No. 131 "Disclosures about Segments of an Enterprise and Related Information" which is effective for years beginning after December 15, 1997. SFAS No. 131 established standards for the way the public business enterprises report information about operating segments in annual financial statements and requires that those enterprises report selected information about operating segments in interim financial reports. It also establishes standards for related disclosures about products and services, geographical areas, and major customers. Since SFAS No. 131 is not required to be applied to interim financial statements in the initial year of adoption, the Company is not required to disclose segment information in accordance with SFAS No. 131 until the fiscal year ended July 31, 1999, if applicable. In the Company's first quarter of fiscal 2000 report, and in subsequent quarters, it would present the interim disclosures required by SFAS No. 131 for both fiscal 2000 and 1999, if applicable. Management does not expect that adoption of SFAS No. 131 will have a significant impact on the Companies determination of its operating segments.

In fiscal 1997, the Company adopted Statement of Financial Accounting Standards ("SFAS") No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of". SFAS No. 121 establishes the accounting for the impairment of long-lived assets, certain identifiable intangibles and the excess of cost over net assets acquired, related to those assets to be held and used in operations, whereby impairment losses are required to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less

than the assets carrying amount. SFAS No. 121 also addresses the accounting of long-lived assets and certain identifiable intangibles that are expected to be disposed of. The adoption of SFAS No. 121 did not have a material effect on the consolidated results of operations or financial condition of the Company.

In fiscal 1998, the Company adopted the provisions of SFAS No. 128, "Earnings Per Share", which was effective for both interim and annual financial statements for periods ending after December 15, 1997. SFAS 128 replaced the previously reported primary and fully diluted earnings per share with basic and diluted earnings per share. Unlike primary earnings per share, basic earnings per share excludes any dilutive effects of options and warrants. Diluted earnings per share is very similar to the previously reported fully diluted earnings per share. All earnings per share amounts for all periods have been presented, and where necessary, restated to conform to SFAS 128 requirements.

The following table sets forth the computation of basic and diluted earnings per share pursuant to SFAS 128.

<TABLE>
<CAPTION>

	Nine Months Ended April 30,		Three Months Ended April 30,	
	1999	1998	1999	1998
	(In Thousands, except per share data)			
<S>	<C>	<C>	<C>	<C>
Numerator:				
Net income for numerator for basic and diluted earnings per common share	$ 3,705	$ 1,984	$ 1,682	$ 903
Denominator:				
Denominator for basic earnings per common share during the period	24,901	24,483	24,907	24,463
Effect of dilutive securities Employee and director stock options and warrants	619	1,067	623	1,067
Denominator for diluted earnings per common equivalent share and assumed conversions	25,520	25,550	25,530	25,530
Basic earnings per share	$ .15	$ .08	$ .07	$ .04
Diluted earnings per share	$ .15	$ .08	$ .07	$ .04

</TABLE>

2. On October 19, 1994 the Company executed a settlement agreement with Johnson & Johnson, Inc. in the aggregate amount of $35.0 million pursuant to which the Company received $ 15.0 million, and a promissory note requiring Johnson & Johnson and its subsidiary, Ortho Diagnostics, Inc., to pay $5.0 million a year

for each of the four successive anniversaries of said date. As of April 30, 1999 all four payments have been received. Pursuant to the terms of the settlement, all of the Company's grants, licenses and intellectual property have been returned to the Company in totality.

On June 1, 1998, the U.S. District Court for the District of Delaware issued its final decision in a case filed by the Company against Calgene in March 1993 and a second case filed by the Company against Calgene in February 1994. Both cases involved claims by the Company that Calgene had infringed patents held by the Company concerning genetic antisense. Calgene filed a counterclaim in the second Delaware action seeking a declaration of invalid on a third patent belonging to the Company. In its decision the court held two of the Company's three antisense patents were invalid, and not infringed. The court declined to act on Calgene's claim that the Company's third antisense patent was invalid citing lack of evidence. The court further held that the Calgene antisense patent was not invalid. The Company has appealed the district court's judgement to the U.S. court of appeals for the Federal Circuit, and Calgene cross-appealed as to the Company's third patent. Oral argument on the appeal was heard on May 4, 1999. A decision is expected by the by the end of 1999. There can be no assurance that the company will be successful in its appeal. If the Company is successful in its appeal, it expects that the case would be remanded for further proceedings before the district court, and there can be no assurance that the Company will be successful in such further proceedings. However, even if the Company is not successful, management does not believe there will be a significant monetary impact.

Item 2- Management's Discussion and Analysis of Financial Condition and Results of Operations

LIQUIDITY AND CAPITAL RESOURCES

The Company at April 30, 1999, had cash and cash equivalents of $41,863,000 an increase of $8,320,000 from July 31,1998. The Company had working capital of $57,278,000 at April 30, 1999 compared to $52,973,000 at July 31,1998.

The Company's net income before taxes for the nine months ended April 30,1999 was $3,858,000 which includes depreciation and amortization aggregating approximately $1,422,000. The Company's positive cash flow from

operations was sufficient to meet its current cash needs for the research and development programs and other investing activities.

Net cash provided by operating activities for the nine month period ended April 30, 1999 was approximately $9,202,000 and included $5.0 million of cash received in connection with the litigation settlement with Johnson & Johnson, Inc. as compared to net cash provided by operating activities of $7,300,000 for the 1998 period which also included $ 5.0 million of cash received in connection with the litigation settlement with Johnson & Johnson, Inc. The increase in net cash provided by operating activities from the 1998 period to the 1999 period was primarily due to the Company's increase in net income.

Net cash used in investing activities increased by $338,000 from the 1998 period primarily as a result of an increase in capital expenditures.

Net cash provided by financing activities decreased by $18,000 from the 1998 period primarily as a result of the decrease in proceeds from the exercise of stock options.

RESULTS OF OPERATIONS

NINE MONTHS ENDED APRIL 30,1999 COMPARED WITH NINE MONTHS ENDED APRIL 30, 1998

Revenues from operations for the nine month period ended April 30,1999 increased by $3,381,000 compared to revenues from operations for the nine month period ended April 30, 1998. This increase was due to an increase of $563,000 in revenue from the clinical reference laboratory operation and by the increase of $2,818,000 of research product sales. The increase in research product sales resulted primarily from an increase in the sales from the Company's non-exclusive distribution agreements. The increase in revenues from the clinical reference laboratory operations resulted primarily from an increase in higher priced screening tests and an increase in esoteric testing revenue.

Cost of sales increased by approximately $735,000 as a result of a increase in the cost of clinical laboratory services of $138,000 and an increase of $597,000 in the cost of sales of research products from the Company's distribution agreements activities.

The provision for uncollectable accounts receivable increased by $227,000 primarily due to a decrease in reimbursement rates from third party insurance carriers. The health care industry is undergoing significant change as third-party payors, such as Medicare and other insurers, increase their efforts to control the cost, utilization and delivery of health care services. In particular, the Company believes that reductions in reimbursement for Medicare services will continue to be implemented form time to time. Reductions in the reimbursement rates of other third-party payors are likely to occur as well. Furthermore, the Company cannot predict the effect health care reform, if enacted, would have on its business, and there can be no assurance that such reforms, if inacted, would not have a material adverse effect on the Company's business and operations.

Research and development expenses increased by approximately $449,000 as a result of an increase in expenses associated with the research programs.

General and Administrative expenses increased approximately by $269,000, primarily due to an increase in legal fees.

The provision for income taxes for the nine months ended April 30, 1999 and 1998 are based on the alternative minimum tax method and current state and local income taxes provided relate primarily to taxes computed based upon capital.

THREE MONTHS ENDED APRIL 30,1999 COMPARED WITH THREE MONTHS ENDED APRIL 30, 1998

Revenues from operations for the three month period ended April 30,1999 increased by $1,496,000 compared to revenues from operations for the three month period ended April 30, 1998. This increase was due primarily to an increase of $1,487,000 of research products sales. The increase in research product sales resulted primarily from an increase in the sales from the Company's non-exclusive distribution agreements.

Cost of sales increased by approximately $280,000 as a result of an increase in the cost of clinical laboratory services of $47,000 and an increase of $233,000 in the cost of sales of research products from the Company's distribution agreements activities.

Research and development expenses increased by approximately $274,000 as a result of an increase in expenses associated with the research programs.

The provision for uncollectable accounts receivable increased by $252,000 primarily due to a decrease in reimbursement rates from third party insurance carriers. The health care industry is undergoing significant change as third-party payors, such as Medicare and other insurers, increase their efforts to control the cost, utilization and delivery of health care services. In particular, the Company believes that reductions in reimbursement for Medicare services will continue to be implemented from time to time. Reductions in the reimbursement rates of other third-party payors are likely to occur as well. Furthermore, the Company cannot predict the effect health care reform, if enacted, would have on its business, and there can be no assurance that such reforms, if enacted, would not have a material adverse effect on the Company's business and operations.

General and Administrative expenses decreased by approximately $78,000, primarily due to a decrease in legal fees.

The provision for income taxes for the three months ended April 30, 1999 and 1998 are based on the alternative minimum tax method and current state and local income taxes provided relate primarily to taxes computed based upon capital.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

(registrant)

Date: June 11, 1999

by: /s/ SHAHRAM K. RABBANI

Chief Operating Officer,
Secretary and Treasurer

<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE QUALIFIED PERIOD ENDED APRIL 30, 1999 AND IS QUALIFIED BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>	<C>
<PERIOD-TYPE>	9-MOS
<FISCAL-YEAR-END>	JUL-31-1999
<PERIOD-START>	AUG-31-1998
<PERIOD-END>	APR-30-1999
<CASH>	41,863
<SECURITIES>	0
<RECEIVABLES>	27,863
<ALLOWANCES>	(13,386)
<INVENTORY>	1,393
<CURRENT-ASSETS>	59,069
<PP&E>	9,993
<DEPRECIATION>	(7,374)
<TOTAL-ASSETS>	75,401
<CURRENT-LIABILITIES>	1,791
<BONDS>	0
<PREFERRED-MANDATORY>	0
<PREFERRED>	0
<COMMON>	249
<OTHER-SE>	92,270
<TOTAL-LIABILITY-AND-EQUITY>	75,401
<SALES>	33,718
<TOTAL-REVENUES>	33,718
<CGS>	12,225
<TOTAL-COSTS>	31,335
<OTHER-EXPENSES>	11,225
<LOSS-PROVISION>	7,885
<INTEREST-EXPENSE>	(1,475)
<INCOME-PRETAX>	3,858
<INCOME-TAX>	153
<INCOME-CONTINUING>	3,705
<DISCONTINUED>	0
<EXTRAORDINARY>	0
<CHANGES>	0
<NET-INCOME>	3,705
<EPS-BASIC>	.15
<EPS-DILUTED>	.15

</TABLE>